anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The purpose of this randomised study was to determine whether dose-intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases results in increased rates of pain improvement compared with conventional external beam radiotherapy (cEBRT) (control) 6 months after treatment.
METHODS: This randomized, controlled phase 3 trial was conducted between November 2016 and January 2023, when it was stopped early. Patients were eligible if they were aged 18 years or older; had one or two painful, stable, or potentially unstable vertebral metastases; and had a life expectancy of 1 year or longer according to the investigator's estimates. Patients received 48.5 grays (Gy) in 10 fractions (with epidural involvement) or 40 Gy in five fractions (without epidural involvement) in the SBRT group and 30 Gy in 10 fractions or 20 Gy in five fractions in the cEBRT group, respectively. The primary end point was an improvement in the pain score at the treated site by at least 2 points (on a visual analog scale from 0 to 10 points) at 6-month follow-up. Data were analyzed on an intention-to-treat and per-protocol basis.
RESULTS: Of 214 patients who were screened for eligibility, 63 were randomized 1:1 between SBRT (33 patients with 36 metastases) and cEBRT (30 patients with 31 metastases). The median age of all patients was 66 years, and 40 patients were men (63.5%). In the intention-to-treat analysis, the 6-month proportion of patients who had metastases with pain reduction by 2 or more points was significantly higher in the SBRT group versus the control group (69.4% vs. 41.9%, respectively; two-sided p = .02). Changes in opioid medication intake relative to baseline were nonsignificant between the groups. No differences were observed in vertebral compression fracture or adverse event rates between the groups.
CONCLUSIONS: Dose-intensified SBRT improved pain score more effectively than cEBRT at 6 months.
Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
Tubular activation and deposition of filtered complement proteins have been implicated in the progression of proteinuric kidney disease. The potent C3b-specific nanobody inhibitor of the alternative pathway, EWE-hC3Nb1, is likely freely filtered in the glomerulus to allow complement inhibition in the tubular lumen and may provide a novel treatment option to prevent tubulointerstitial injury. However, more information on the pharmacokinetic properties and renal tubular handling of EWE-hC3Nb1 nanobody is required for its pharmacological application in relation to kidney disease. Here, we examined the pharmacokinetic properties of free EWE-hC3Nb1 in mouse plasma and urine, following subcutaneous injection in wild-type control and podocin knock out (KO) mice with severe proteinuria. Tubular handling of filtered EWE-hC3Nb1 was assessed by immunohistochemistry (IHC) on kidney tissue from control, proteinuric mice, and KO mice deficient in the proximal tubule endocytic receptor megalin. Rapid plasma absorption and elimination of EWE-hC3Nb1 was observed in both control and proteinuric mice; however, urinary excretion of EWE-hC3Nb1 was markedly increased in proteinuric mice. Urinary EWE-hC3Nb1 excretion was amplified in megalin KO mice, and substantial accumulation of EWE-hC3Nb1 was observed in megalin-expressing renal proximal tubules by IHC. Moreover, free EWE-hC3Nb1 was found to be rapidly cleared from plasma. In conclusion, filtered EWE-hC3Nb1 is reabsorbed by a megalin-dependent process in the proximal tubules. Increased load of filtered proteins in the tubular fluid may inhibit the megalin-dependent uptake of EWE-hC3Nb1 in proteinuric mice. Treatment with EWE-hC3Nb1 may allow investigation of the effects of complement inhibition in the tubular fluid.
INTRODUCTION AND HYPOTHESIS: The objective was to validate the translated Russian version of the prolapse quality-of-life (P-QoL) questionnaire and test its applicability to assess the impact of pelvic organ prolapse (POP) on QoL and the effect of treatment in women undergoing reconstructive surgery.
METHODS: Following a forward- and back-translation of the original English P-QOL questionnaire into Russian, the translated questionnaire was reviewed by a group of patients as well as an expert panel. Women with POP who were admitted to a university hospital for reconstructive surgery were recruited. All the women completed the P-QoL questionnaire, Pelvic Floor Distress Inventory (PFDI-20) and 36-Item Short Form Survey (SF-36) questionnaires before surgery. Clinical data and POP Quantification (POP-Q) Index according to the International Continence Society were obtained. Psychometric properties of the questionnaire were assessed.
RESULTS: A total of 303 women with POP were included in the study. Most patients presented with POP-Q >2. The P-QoL questionnaire demonstrated good psychometric properties. High internal consistency was shown in all domains (Cronbach's alpha coefficient from 0.65 to 0.92). The test-retest reliability confirmed a highly significant stability between the total scores for each domain. Significant correlations of the P-QoL domains with the PFDI-20 and SF-36 scales (p < 0.05) were obtained, demonstrating satisfactory convergent validity. Discriminative construct validity was proved by the differences in the mean scores for P-QoL domains across POP-Q stages (p < 0.05): general health perceptions, role limitations, physical limitations, social limitations and severity measures were significantly higher for POP-Q stages 3 and 4 than for POP-Q stage 2 (p < 0.01); general health perceptions and severity measures were higher for POP-Q stage 4 than for POP-Q stage 3 (p < 0.05); sleep/energy was higher for POP-Q stage 3 than for POP-Q stage 2 (p < 0.05). Significant improvement of QoL in the 2 months after surgery (p < 0.05) indicated that the P-QoL questionnaire is sensitive to change.
CONCLUSIONS: The Russian version of the P-QoL questionnaire is characterized by appropriate psychometric properties. The P-QoL questionnaire is a useful tool for describing the QoL profile in women with POP before reconstructive surgery and evaluating treatment outcomes after the procedure.
The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
The participants will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 120% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
Since the presence of tinnitus is not always associated with audiometric hearing loss, it has been hypothesized that hidden hearing loss may act as a potential trigger for increased central gain along the neural pathway leading to tinnitus perception. In recent years, the study of hidden hearing loss has improved with the discovery of cochlear synaptopathy and several objective diagnostic markers. This study investigated three potential markers of peripheral hidden hearing loss in subjects with tinnitus: extended high-frequency audiometric thresholds, the auditory brainstem response, and the envelope following response. In addition, speech intelligibility was measured as a functional outcome measurement of hidden hearing loss. To account for age-related hidden hearing loss, participants were grouped according to age, presence of tinnitus, and audiometric thresholds. Group comparisons were conducted to differentiate between age- and tinnitus-related effects of hidden hearing loss. All three markers revealed age-related differences, whereas no differences were observed between the tinnitus and non-tinnitus groups. However, the older tinnitus group showed improved performance on low-pass filtered speech in noise tests compared to the older non-tinnitus group. These low-pass speech in noise scores were significantly correlated with tinnitus distress, as indicated using questionnaires, and could be related to the presence of hyperacusis. Based on our observations, cochlear synaptopathy does not appear to be the underlying cause of tinnitus. The improvement in low-pass speech-in-noise could be explained by enhanced temporal fine structure encoding or hyperacusis. Therefore, we recommend that future tinnitus research takes into account age-related factors, explores low-frequency encoding, and thoroughly assesses hyperacusis.
Employment is important for financial security, social connection, and life satisfaction. Unfortunately, rates of unemployment remain high among people with spinal cord injury (SCI) and brain injury (BI). To help address this challenge, the investigators are conducting a single-site, randomized, controlled trial to compare two programs intended to increase rates of employment among people with SCI or BI. In one program, services are coordinated by a counselor employed by the New Jersey State Division of Vocational Rehabilitation Services, a state-based agency that assists people with disabilities who are interested in pursuing employment. In the other program, services are coordinated by a facilitator who is employed by the rehabilitation hospital at which the participant receives inpatient care. Services provided in both programs will be customized to the participant's needs and goals. Services will begin in inpatient rehabilitation and may include education, therapy, equipment provision, counseling, and other interventions.

The project will enroll 500 participants who are interested in becoming employed or returning to work. Information about employment status, earnings, benefits use, community participation, and health will be collected through a combination of surveys, medical record review, and information available in state and federal administrative databases. Analyses will examine the rate of participants employed at 1 year after enrollment in each group, time to employment, earnings, benefits usage, community participation, and well-being. Findings from this study will be used to determine which ways of delivering services are most effective in enabling employment, and to provide information to help other rehabilitation centers adopt effective programs.
PURPOSE: A steamed green tea extract is provided to treat atopic dermatitis through a histamine test, and to develop a cosmetic product, a drug, and food for treating atopic dermatitis. CONSTITUTION: A composition for treating atopic dermatitis contains a hot water extract or an ethanol extract of steamed green tea, or a mixture thereof as active ingredient. The composition also contains the hot water extract, the ethanol extract, a hot water extract of non-streamed green tea, and an ethanol extract of non-steamed green tea in a weight ratio of 1:1:1:1. Green tea is steamed at 121 deg. C for 30-60 minutes(S120). [Reference numerals] (S110) Non-used green tea leave and stem preparing step; (S120) Steam pre-processing step; (S130) Hot water extracting or ethanol extracting step; (S140) Filtering step; (S150) Concentrating step; (S160) Freeze drying step
PURPOSE:To use a substance as an active ingredient of a remedy for hepatic diseases, by partitioning a CH3OH-CHCl3 extracted essence of a cockroach belonging to the family Epilampridae with CHCl3-water, extracting the soluble substance from the water layer and the CHCl3 layer with a specific solvent. CONSTITUTION:A cockroach preferably Opisthophlatic orientalis Bur. belonging to the family Epilampridae is heated in a CH3OH-CHCl3 mixed solution under reflux, the solvent is distilled away, to give a liquid immersed extract. The extract is partitioned with CHCl3-water, (A) the water layer is extracted with butanol to give a butanol-soluble substance, or (B) the CHCl3 layer is partitioned with hexane-hydrous methanol to give a hexane-soluble substance. Or, (C) the hydrous methanol layer of the partition B is extracted with CCl4 to give a CCl4-soluble substance. The soluble substances A-C are found to have remedying efect on hepatic diseases and useful as a remedy for hepatic diseases.
Background: Cardiovascular diseases, including coronary heart disease (CHD), are currently positioned among the leading causes of mortality globally. Risk factors of CHD include, among others, hypercholesterolemia and elevations in systemic inflammation. Functional foods enriched with compounds showing cholesterol-lowering effects are considered one among various dietary and lifestyle intervention strategies to tackle this problem. A CHD-preventive effect of dietary plant sterols has been broadly discussed, not only due to their ability to reduce blood cholesterol level, but also to their proven anti-inflammatory potential. Palm oil is one of the most widely consumed edible oils in the world. Despite its widespread use, especially in Asian countries, no study has been conducted using palm oil as a vehicle for plant sterols. Methods: The aim of the placebo-controlled double-blinded trial presented here was, therefore, to evaluate the effect of palm oil enriched with plant sterols, used as a cooking oil, on lipid profile and systemic inflammation marker in 100 adult hyperlipidemic residents of Bogor, Indonesia. Results: The study has shown a significant reduction in total cholesterol and LDL cholesterol level in study subjects consuming plant sterol-enriched palm oil as a replacement for usual palm oil for cooking, with no similar effect on CRP levels. Conclusions: The study suggests that, along with a healthy diet and lifestyle promotion, incorporating plant sterols in palm oil used for cooking may be an effective strategy to reduce cardiovascular risks in hyperlipidemic individuals.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention concerns a pharmaceutical industry, in particular to a medicinal preparation for treatment of cardiovascular and cerebrovascular diseases. A medicinal preparation for treatment of the cardiovascular and cerebrovascular diseases, containing iso lithis sperm acids A and B which are characterised in mass spectra by certain peaks. The way of manufacturing of a medicinal preparation including weighing of Radix Salviae Miltiorrhizae and Radix Notoginseng; addition of a hydroxide of sodium, Sodium hydrogenum, sodium carbonate, potassium hydroxide, potassium bicarbonate, potassium carbonate or their admixture in certain quantity; boiling of admixtures in 3-6-time quantity of water 2-4 times; filtration of an admixture and concentration of incorporated filtrates; addition of ethanol infusion of an admixture and separation of the supernatant liquid; allocation of ethanol from the supernatant liquid and concentration of the rest with reception of extract Radix Salviae Miltiorrhizae - Radix Notoginseng, mixing of the received extract with borneol or oil Lignum Dalbergie Odoriferae (rosewood); and excipient addition. ^ EFFECT: development of a preparation, effective for treatment of cardiovascular and cerebrovascular diseases. ^ 11 cl, 6 dwg, 7 tbl, 9 ex
BACKGROUND: The feasibility and safety of laparoscopic pancreaticoduodenectomy (LPD) in overweight patients is still controversial. This study was designed to analyze the impact of overweight on surgical outcomes in patients undergoing LPD.
METHODS: Data from patients who underwent LPD between January 2018 and July 2022 were analyzed retrospectively. A 1:1 propensity score-matching (PSM) analysis was performed to minimize bias between groups.
RESULTS: A total of 432 patients were enrolled, with a normal weight group (n = 241) and an overweight group (n = 191). After matching, 144 patients were enrolled in each group. The results showed that the incidence of clinically relevant postoperative pancreatic fistula (CR-POPF) and delayed gastric emptying (DGE) was significantly higher in the overweight group compared to the normal weight group (P = 0.036). However, there were no significant differences in perioperative mortality (1.4% vs. 2.1%, P = 0.652) and long-term survival outcomes between malignancy patients with different body mass index (BMI) before and after PSM (all P > 0.05).
CONCLUSIONS: It is safe and feasible for overweight patients to undergo LPD with mortality and long-term survival outcomes comparable to the normal weight group. High-quality prospective randomized controlled trials are still needed.
The dosage of Sodium Chloride Injection, USP, 23.4%, as an additive in parenteral fluid therapy is predicated on specific requirements of the patient after necessary clinical and laboratory information is considered and correlated. The appropriate volume is then withdrawn for proper dilution. Having determined the milliequivalents of sodium chloride to be added, divide by four to calculate the numbers of milliliters (mL) of sodium chloride to be used. Withdraw this volume aseptically and transfer the additive solution into appropriate intravenous solutions such as 5% Dextrose Injection. The properly diluted solutions may be given intravenously. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. 

Directions for Proper Use of Pharmacy Bulk Package

Use Aseptic Technique

  1. During use, container must be stored and all manipulations performed in an appropriate laminar flow hood. 
  2. To hang the bottle use the attached hanger. 
  3. Remove fliptop cap from vial and cleanse closure with antiseptic. 
  4. Insert suitable sterile dispensing set or transfer device and suspend unit in a laminar flow hood. The closure should be entered only once and after initial entry, the withdrawal of container contents should be completed promptly in one continuous operation. Should this not be possible, a maximum time of 4 hours from initial closure puncture is permitted to complete fluid transfer operations; i.e., discard container no later than 4 hours after initial closure puncture. 
  5. Sequentially dispense aliquots of Sodium Chloride Injection, USP, 23.4% into intravenous containers using appropriate transfer device. During fluid transfer operations, the Pharmacy Bulk Package should be maintained under the storage conditions recommended in the labeling. 
  6. Inspect solution after admixing. Discard if the solution is discolored or particulates are observed.
NEW MATERIAL:The compound of formula I (X<1> and X<2> are halogen; the substitution position of X<2> is 5 or 6; R<1> is formyl, carboxyl or lower alkoxycarbonyl; R<2> is H or lower alkyl). EXAMPLE:4-Bromo-5-iodo-3-indolecarbaldehyde. USE:It exhibits bactericidal action, antiviral action and plant growth promoting action by itself. Useful as pharmaceuticals such as antibacterial agent and antiviral agent, agricultural chemicals such as plant-growth promoting agent and herbicide or their intermediate or as production intermediates for various compounds having dihalogenoindole skeleton of the compound of formula I. PREPARATION:A compound of formula I wherein R<1> is formyl can be produced e.g. by reacting a compound of formula II with thallium tristrifluoroacetic acid and reacting the resultant compound of formula III with a halide such as KI, cupric bromide or cupric chloride. The obtained compound can be converted into another compound of formula I wherein R<1> is other than formyl by oxidizing and esterifying the above compound.
The invention belongs to the field of biomedicine, and particularly relates to application of macrophages expressing IL-4 protein in treating obesity and regulating and controlling blood sugar. The application of macrophages and compositions containing macrophages is as follows: (1) the application in the preparation of products for treating obesity. (2) The use in the manufacture of a product for lowering blood glucose. (3) The application in preparing products for treating diabetes caused by obesity. The macrophage is a macrophage expressing IL-4 protein. The macrophage expressing IL-4 protein, namely RAW264.7 cells infected by lentivirus pCDH-IL-4, prepared by the invention is used for carrying out intraperitoneal injection on obese mice, so that the weight of the mice can be effectively reduced, and the blood sugar level of the mice after glucose is taken up can be reduced. Therefore, the macrophage expressing the IL-4 protein can treat obesity and reduce blood sugar, provides a new treatment medicament and method for clinically treating obesity and other diseases such as diabetes caused by obesity, and has important application value for treating obesity and other diseases such as diabetes caused by obesity.
Post intubation tracheal stenosis (PI) was recognized in 1880, after prolonged endotracheal intubation in 4 patients with upper airway obstruction.The most common causes of acquired tracheal stenosis are endotracheal intubation and tracheostomy. Tracheal stenosis is a surgical problem managed non operatively by bronchoscopic dilation, endoluminal treatment with lasers, and stenting. Bronchoscopic management have a good success rate. PI and post tracheostomy stenosis (PT) are recognized with an 4.9 cases per million per year in the general population. Prolonged intubation can result in tracheal stenosis at various levels within the trachea.Tracheal stenosis occurs at the endotracheal tube cuff site in one third of the reported PI cases \[9\] and appears as a web-like fibrous. The mainly postulated cause is loss of regional blood flow.This injury begins within the first hours of intubation, and healing of the damaged areas within 3 to 6 weeks. Large volume, low pressure cuffs has reduced the occurrence of cuff injury.Patients in the ICU are common to have respiratory involvement, with 30-50% of the admissions requiring the use of mechanical ventilation.Flexible bronchoscopy has become the procedure of choice in most examinations of the tracheobronchial tree.The incidence of PI tracheal stenosis ranges from 6-21% and following tracheostomy ranges from 0.6-21%.
PCT No. PCT/BE91/00048 Sec. 371 Date Feb. 19, 1993 Sec. 102(e) Date Feb. 19, 1993 PCT Filed Jul. 18, 1991 PCT Pub. No. WO92/01466 PCT Pub. Date Feb. 6, 1992.Prophylactic and therapeutic applications of peroxidases for the manufacture of medicaments for the treatment and prevention and treatment of enveloped virus infections and, in particular, of herpes simplex and immunodeficiency virus infections. The medicaments include a peroxidase, a substrate and a peroxide in a pharmaceutically acceptable carrier. Peroxidases of the medicaments include lactoperoxidase and myeloperoxidase. The medicaments are formulated with a pharmaceutically acceptable carrier for topical, oral and injectable administration to individuals in need thereof.